FDA-cleared profile

CT 5300

Philips Healthcare (Suzhou) Co., Ltd. · CT/CTA · FDA-cleared (510(k))

CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.

Clinical role
Diagnostic CT acquisition, reconstruction, review, and protocol-governed low-dose lung-cancer screening.
Images and patients
CT/CTA · Multi-region
Key limitation
The screening must be performed within the established inclusion criteria of programs or protocols approved and published by a governmental body or professional medical society. Precise Image has not been validated for lung cancer screening indications.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyCT/CTA · Multi-region
  • Workflow roleDiagnostic CT acquisition, reconstruction, review, and protocol-governed low-dose lung-cancer screening.
  • Required inputX-ray transmission data taken at different angles and planes.
  • Output and human actionCross-sectional images of the body taken at different angles and planes.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Diagnostic CT acquisition, reconstruction, review, and protocol-governed low-dose lung-cancer screening.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
X-ray transmission data taken at different angles and planes.
  • Exact FDA submission
  • Checked 2026-09-19

This is the packet's direct description of the reconstructed CT input.

Output and clinician action
Cross-sectional images of the body taken at different angles and planes.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states this output; the current dose and examination-information wording is not a direct packet output statement.

Care setting
Hospital and outpatient diagnostic CT departments.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
The screening must be performed within the established inclusion criteria of programs or protocols approved and published by a governmental body or professional medical society. Precise Image has not been validated for lung cancer screening indications.
  • Exact FDA submission
  • Checked 2026-09-19

The replacement uses the packet's explicit lung-screening boundary and Precise Image validation limitation.

Evidence summary
K232491 describes manufacturer electrical, radiation, image-quality, dose, software, and system validation. Current vendor phantom claims provide evaluation inputs but should retain their reconstruction, dose, and object-size conditions.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K232491 describes manufacturer electrical, radiation, image-quality, dose, software, and system validation. Current vendor phantom claims provide evaluation inputs but should retain their reconstruction, dose, and object-size conditions.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K232491 FDA performance package for CT 5300

  • DesignManufacturer bench, phantom, image-quality, dose, software, electrical-safety, and system verification
  • PopulationRepresentative adult and pediatric head and body CT protocols, including approved low-dose lung screening
  • Scopeexact submission
  • Tested versionCT 5300 cleared in K232491
  • IndependenceSponsor or vendor study

K232491

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
2 reviewed FDA recall records in the 2026-09-02 openFDA snapshot natively identify K232491. Read the model- and version-scoped events and confirm affected-unit and correction status with the manufacturer. FDA recall Z-0376-2026 affects CT 5300 software 5.1.0.X and 5.1.1.X and describes six motion, dose-setting, ECG-file, orientation, preview-display, and manual-ROI issues that could produce unusable imaging, additional exposure, or rescanning. FDA lists the recall as open and classified. FDA recall Z-0882-2026 affects CT 5300 software versions 4.5, 5.0, and 5.1 because improperly tightened heat-exchanger screws after replacement could allow a component to detach inside the rotating scanner. FDA lists the recall as open and classified.
  • FDA source
  • Exact product version
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0376-2026

Open, Classified

2025-10-27

Exact CT 5300 model and software-version match. Review the full FDA event, installed version, field correction, and local exposure to each of the six conditions.

recall: Z-0882-2026

Open, Classified

2025-12-03

Exact CT 5300 model and software-version match. Confirm whether the tube heat exchanger was replaced and whether the inspection or correction was completed.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray transmission data taken at different angles and planes.

    Scope: Exact FDA submission. This is the packet's direct description of the reconstructed CT input.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K232491: CT 5300

  2. Routing

    Source context, not route validation: DICOM and IHE integration is documented for current Philips CT products; test exact software, worklist, PACS, dose-report, reconstruction, and advanced-object interoperability.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K232491: CT 5300 · CT 5300 product overview

  3. AI processing

    Source context, not route validation: Installed CT scanner with model-specific gantry, table, console, reconstruction hardware, networking, shielding, power, cooling, and service requirements.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K232491: CT 5300 · CT 5300 product overview

  4. Returned objects

    Source context, not route validation: Cross-sectional images of the body taken at different angles and planes.

    Scope: Exact FDA submission. The exact device description states this output; the current dose and examination-information wording is not a direct packet output statement.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K232491: CT 5300

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional images of the body taken at different angles and planes.

    Scope: Exact FDA submission. The exact device description states this output; the current dose and examination-information wording is not a direct packet output statement.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K232491: CT 5300

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed CT scanner with model-specific gantry, table, console, reconstruction hardware, networking, shielding, power, cooling, and service requirements.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM and IHE integration is documented for current Philips CT products; test exact software, worklist, PACS, dose-report, reconstruction, and advanced-object interoperability.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.

Training
Only qualified ct technologists and physicians trained in diagnostic ct and protocol selection. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Vendor image-quality and dose claims are based on stated phantom comparisons and are not guaranteed patient outcomes. Verify pediatric protocols, lung-screening eligibility, dose monitoring, cardiac options, and installed software.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K232491 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM and IHE integration is documented for current Philips CT products; test exact software, worklist, PACS, dose-report, reconstruction, and advanced-object interoperability.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Vendor image-quality and dose claims are based on stated phantom comparisons and are not guaranteed patient outcomes. Verify pediatric protocols, lung-screening eligibility, dose monitoring, cardiac options, and installed software.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Vendor image-quality and dose claims are based on stated phantom comparisons and are not guaranteed patient outcomes. Verify pediatric protocols, lung-screening eligibility, dose monitoring, cardiac options, and installed software.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232491
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet identifies the device as a Computed Tomography X-Ray System; it does not establish the dossier's CT/CTA value. Controlled directory display reconciled from exact FDA wording: Computed Tomography X-Ray System. -> CT/CTA.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-05-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
9Source classes checked
0Awaiting review PubMed leads
5Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 5 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 5 FDA recall candidates were manually reviewed: 2 published and 3 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 5 postmarket candidate records; 5 have been reviewed (2 published, 3 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 2 history items

Source ledger

  1. FDA K232491: CT 5300

    U.S. Food and Drug Administration - Published 2024-05-03 - Accessed 2026-09-19

    Scope: purpose, anatomy, modality, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-0376-2026: Model: CT 5300; Product Code (REF): 728285; Software Versions: 5.1.0.X & 5.1.1.X;

    U.S. Food and Drug Administration - Published 2025-10-27 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-0882-2026: CT 5300; Software Version Number: 4.5, 5.0, 5.1;

    U.S. Food and Drug Administration - Published 2025-12-03 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  6. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  7. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  8. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  9. CT 5300 product overview

    Philips - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, implementationCapabilities, currentCommercialContext

  10. Philips: Responsible Disclosure Statement

    Philips - Accessed 2026-10-26

    Scope: security

Research history

  1. K232491 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K243523

NAEOTOM Alpha.Peak/ NAEOTOM Alpha; NAEOTOM Alpha.Pro; NAEOTOM Alpha.Prime

Siemens Medical Solutions USA, Inc.

Authorized purpose: NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2025-02-12
FDA-cleared K233657

NAEOTOM Alpha

Siemens Medical Solutions USA, Inc.

Authorized purpose: NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2024-03-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history